NO20015367D0 - Pegylert interferon <alfa>-CCR5-antagonist-kombinasjons HIV- terapi - Google Patents

Pegylert interferon <alfa>-CCR5-antagonist-kombinasjons HIV- terapi

Info

Publication number
NO20015367D0
NO20015367D0 NO20015367A NO20015367A NO20015367D0 NO 20015367 D0 NO20015367 D0 NO 20015367D0 NO 20015367 A NO20015367 A NO 20015367A NO 20015367 A NO20015367 A NO 20015367A NO 20015367 D0 NO20015367 D0 NO 20015367D0
Authority
NO
Norway
Prior art keywords
alpha
pegylated interferon
ccr5 antagonist
antagonist combination
hiv therapy
Prior art date
Application number
NO20015367A
Other languages
English (en)
Other versions
NO328679B1 (no
NO20015367L (no
Inventor
Mark A Laughlin
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20015367D0 publication Critical patent/NO20015367D0/no
Publication of NO20015367L publication Critical patent/NO20015367L/no
Publication of NO328679B1 publication Critical patent/NO328679B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20015367A 1999-05-04 2001-11-02 Anvendelse av et pegylert interferon-alfa og en CCR5-antagonist for fremstilling av et medikament for behandling av HIV-1-infeksjoner. NO328679B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30489799A 1999-05-04 1999-05-04
PCT/US2000/011634 WO2000066141A2 (en) 1999-05-04 2000-05-01 Pegylated interferon alfa-ccr5 antagonist combination hiv therapy

Publications (3)

Publication Number Publication Date
NO20015367D0 true NO20015367D0 (no) 2001-11-02
NO20015367L NO20015367L (no) 2002-01-03
NO328679B1 NO328679B1 (no) 2010-04-26

Family

ID=23178462

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015367A NO328679B1 (no) 1999-05-04 2001-11-02 Anvendelse av et pegylert interferon-alfa og en CCR5-antagonist for fremstilling av et medikament for behandling av HIV-1-infeksjoner.

Country Status (21)

Country Link
EP (1) EP1175224B1 (no)
JP (1) JP2002543144A (no)
CN (1) CN1349408A (no)
AR (1) AR023824A1 (no)
AT (1) ATE289516T1 (no)
AU (1) AU776541B2 (no)
BR (1) BR0010593A (no)
CA (1) CA2365900A1 (no)
DE (1) DE60018273T2 (no)
ES (1) ES2238277T3 (no)
HK (1) HK1039278B (no)
HU (1) HUP0202734A3 (no)
MX (1) MXPA01011116A (no)
MY (1) MY127670A (no)
NO (1) NO328679B1 (no)
NZ (1) NZ514519A (no)
PE (1) PE20010283A1 (no)
PT (1) PT1175224E (no)
TW (1) TWI289454B (no)
WO (1) WO2000066141A2 (no)
ZA (1) ZA200108870B (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050065319A1 (en) * 2000-12-19 2005-03-24 Baroudy Bahige M. Combination method for treating viral infections
TW201018661A (en) 2003-03-14 2010-05-16 Ono Pharmaceutical Co Heterocyclic rinf having nitrogen atom derivatives and medicament containing the derivatives as active ingredient
JPWO2004092136A1 (ja) * 2003-04-18 2006-07-06 小野薬品工業株式会社 含窒素複素環化合物およびその用途
WO2004092169A1 (ja) 2003-04-18 2004-10-28 Ono Pharmaceutical Co., Ltd. スピロピペリジン化合物およびその医薬用途
DE602005002673T2 (de) 2004-04-29 2008-07-24 F. Hoffmann-La Roche Ag Nukleotidsequenzvariation im Gen NS5A als Marker
MX2007002886A (es) 2004-09-13 2007-05-16 Ono Pharmaceutical Co Derivado heterociclico que contiene nitrogeno y un farmaco que contiene el mismo como el ingrediente activo.
KR20070107085A (ko) * 2005-02-23 2007-11-06 쉐링 코포레이션 케모카인 수용체의 억제제로서 유용한 피페리디닐 피페라진유도체
EP1889622A4 (en) 2005-05-31 2009-12-23 Ono Pharmaceutical Co SPIROPIPERIDINE COMPOUND AND MEDICINAL USE THEREOF
PL1942108T3 (pl) 2005-10-28 2014-03-31 Ono Pharmaceutical Co Związek zawierający grupę zasadową i jego zastosowanie
PT1961744E (pt) 2005-11-18 2013-05-15 Ono Pharmaceutical Co Composto que contém um grupo básico e sua utilização
CN101443322A (zh) 2006-03-10 2009-05-27 小野药品工业株式会社 含氮杂环衍生物及含有该衍生物作为活性成分的药物
WO2007132846A1 (ja) 2006-05-16 2007-11-22 Ono Pharmaceutical Co., Ltd. 保護されていてもよい酸性基を含有する化合物およびその用途
US20090325992A1 (en) 2006-07-31 2009-12-31 Ono Pharmaceutical Co., Ltd. Compound having cyclic group bound thereto through spiro binding and use thereof
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
US20140271680A1 (en) 2011-08-12 2014-09-18 Universite Paris-Est Creteil Val De Marne Methods and pharmaceutical compositions for treatment of pulmonary hypertension
EP2780015B1 (en) 2011-11-18 2017-01-04 Heptares Therapeutics Limited Muscarinic m1 receptor agonists
US10272143B2 (en) * 2014-01-08 2019-04-30 Immunovative Therapies Ltd. Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome
GB201519352D0 (en) 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
WO1997016204A1 (en) * 1995-11-02 1997-05-09 Schering Corporation Continuous low-dose cytokine infusion therapy
GB9609932D0 (en) * 1996-05-13 1996-07-17 Hoffmann La Roche Use of IL-12 and IFN alpha for the treatment of infectious diseases
WO1998025617A1 (en) * 1996-12-13 1998-06-18 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
AR013669A1 (es) * 1997-10-07 2001-01-10 Smithkline Beecham Corp Compuestos y metodos

Also Published As

Publication number Publication date
CA2365900A1 (en) 2000-11-09
AU4681500A (en) 2000-11-17
WO2000066141A3 (en) 2001-02-08
HUP0202734A2 (hu) 2002-12-28
PT1175224E (pt) 2005-07-29
ZA200108870B (en) 2003-03-26
AR023824A1 (es) 2002-09-04
EP1175224A2 (en) 2002-01-30
TWI289454B (en) 2007-11-11
DE60018273D1 (de) 2005-03-31
ATE289516T1 (de) 2005-03-15
WO2000066141A2 (en) 2000-11-09
BR0010593A (pt) 2002-02-13
HK1039278B (zh) 2005-06-30
CN1349408A (zh) 2002-05-15
JP2002543144A (ja) 2002-12-17
PE20010283A1 (es) 2001-03-16
EP1175224B1 (en) 2005-02-23
MXPA01011116A (es) 2002-06-04
NO328679B1 (no) 2010-04-26
DE60018273T2 (de) 2005-08-18
ES2238277T3 (es) 2005-09-01
HK1039278A1 (en) 2002-04-19
NZ514519A (en) 2003-07-25
MY127670A (en) 2006-12-29
NO20015367L (no) 2002-01-03
AU776541B2 (en) 2004-09-16
HUP0202734A3 (en) 2003-11-28

Similar Documents

Publication Publication Date Title
NO20015367D0 (no) Pegylert interferon &lt;alfa&gt;-CCR5-antagonist-kombinasjons HIV- terapi
NO20031742D0 (no) Ribavirinpegylert interferon alfa HCV-kombinasjonsterapi
DK1637127T3 (da) Terapeutisk mikroskum
DE50009145D1 (de) Teleskopkran
NO20021443L (no) Antivirale sammensetninger
ID26056A (id) Popok sekali pakai
DE60039612D1 (de) Verbundener konstruktionskörper
ID26389A (id) Popok sekali pakai
NO20022692D0 (no) Terapeutiske midler
ITMI991898A0 (it) Stimolatori di fibroblasti
ID24782A (id) Popok sekali pakai
ID25571A (id) Popok sekali pakai
DE60022294D1 (de) Analog-Digital-Wandleranordnung
NO20003934L (no) Oksydkatalysatorer
DE60037189D1 (de) Rekombinante, natrium-jodid symporter-kodierende adenoviren
NO20034432L (no) Interferon gamma polypeptidvarianter
HK1041434A1 (zh) 抗病毒藥物和乙型肝炎疫苗的聯合
DE60035088D1 (de) Runde Formkörperzusammensetzungen
PL363181A1 (en) Modified interferon alpha with reduced immunogenicity
DE60035826D1 (de) Entfernungsmesser
FR2791348B1 (fr) POLYPEPTIDE Npt2B
ATE519775T1 (de) Rekombinante untereinheiten-impfstoffe
NO995608L (no) Mast
NO20016301D0 (no) Terapeutiske midler
SI1175224T1 (en) Pegylated interferon alfa-ccr5 antagonist combination hiv therapy

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees